查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024933

蛋白質工程市場規模、佔有率、趨勢和預測：按產品/服務、蛋白質類型、技術、最終用戶和地區分類，2026-2034年

Protein Engineering Market Size, Share, Trends and Forecast by Product & Services, Protein Type, Technology, End User and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2025年全球蛋白質工程市場規模為39億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到86億美元，2026年至2034年的複合年成長率（CAGR）為8.74%。目前，北美市場主導地位，預計到2025年將佔據40.6%的顯著市場。人工智慧（AI）驅動的自動化正在推動蛋白質建模、藥物發現和工業酶最佳化，這是蛋白質工程市場佔有率擴張的關鍵因素。政府資助支持學術研究，並加速蛋白質療法和合成生物學領域的創新。

政府資助和學術研究正透過創新和商業化加速蛋白質工程市場的成長。公共研究津貼支持蛋白質結構、功能和生物工程應用的基礎研究。政府機構向大學撥款，用於開發新型蛋白質療法和工業酵素。研究機構與生物技術公司合作，將學術發現轉化為商業性的蛋白質工程解決方案。聯邦政府資助計畫正在推動合成生物學的發展，使各種應用領域能夠實現精確設計的蛋白質。學術研究人員正在最佳化蛋白質表現系統，以提高製藥和工業生物製造的規模化能力。政府支持的舉措正在推動人工智慧驅動的蛋白質建模，從而加強藥物發現和標靶治療的開發。學術研究機構正在開發新的基因編輯技術，以最佳化蛋白質修飾，增強其功能。

人工智慧 (AI) 驅動的自動化正在透過提高效率、準確性和可擴展性來變革美國蛋白質工程市場。機器學習 (ML) 演算法能夠預測蛋白質結構，從而改善藥物發現和生物製藥開發流程。 AI 工具能夠最佳化蛋白質的折疊、穩定性和功能，以應用於治療和工業領域，進而推動蛋白質工程市場的需求。自動化、高效能篩檢能夠加速候選蛋白的選擇，進而降低開發修飾蛋白的時間和成本。深度學習模型能夠分析龐大的生物資料集，以識別具有特定特性的新型蛋白質序列。 AI 驅動的計算生物學能夠增強蛋白質的合理設計，最佳化分子間相互作用，並提高特異性。例如，2024 年 11 月，倫敦帝國學院在舊金山推出了其在美國的首個實體機構—「帝國理工全球美國分部」。該中心專注於人工智慧、機器人、清潔技術、生物技術和工程生物學，目標是在2025年前促成100項新的美英科技夥伴關係。此外，機器人能夠簡化蛋白質純化和表徵流程，最大限度地減少誤差，提高實驗的可重複性。人工智慧整合的實驗室自動化提高了大規模蛋白質表現和生物製造工作流程的效率，進一步推動了市場成長。

蛋白質工程市場趨勢

不斷擴大的合成生物學市場

對合成生物學投資的不斷成長以及對基於蛋白質的藥物研發日益成長的關注是推動市場發展的關鍵因素。根據IMARC Group的報告，2024年全球合成生物學市場規模為185億美元，預計到2033年將達到667億美元，2025年至2033年的複合年成長率（CAGR）為15.3%。科學家正在設計具有更高穩定性、特異性和功能的客製化蛋白質，用於各種工業和醫療應用。人工智慧演算法和基於CRISPR的修飾技術能夠實現針對治療和工業應用的精準蛋白質修飾。這些工程化蛋白質透過提高效率和永續性，正在革新藥物研發、酵素製造和生物基材料領域。企業正在利用合成生物學工具開發用於綠色化學和永續生產方法的新型生物催化劑。微發酵技術正在生產具有更優營養成分和功能的替代蛋白質。源自工程化蛋白質的生物基材料正在紡織和包裝領域取代傳統的石油化學產品。代謝通道工程的進步正在擴展用於增強生物製程應用中酶活性的蛋白質的功能，從而推動市場成長。

蛋白質缺乏症增加

蛋白質缺乏症的高發生率推動了蛋白質工程技術的需求。研究表明，開發中國家1-9歲兒童中有2-10%患有嚴重的蛋白質和熱量營養不良，在某些地區，高達50%的1-5歲兒童患有輕度營養缺乏症。與營養不良相關的疾病以及需要補充蛋白質的遺傳性疾病正在推動蛋白質工程技術的進步。人們正在開發修飾蛋白，以有效解決代謝紊亂、酵素缺乏症和遺傳性蛋白質相關疾病。生技製藥公司正在設計重組蛋白，用於治療囊腫纖維化、血友病和生長激素缺乏症等疾病。蛋白質工程技術的進步使得生產具有更高生物利用度、更穩定和更有效的治療性蛋白質成為可能。研究人員正在修飾蛋白質結構，以提高其吸收率、半衰期和標靶遞送能力，從而應用於臨床。人們對蛋白質缺乏症的日益關注正在推動對用於個人化醫療解決方案的精準工程蛋白的投資。人們對植物來源和發酵蛋白的需求不斷成長，這有助於解決世界各地人們飲食中的蛋白質缺乏問題。

基因工程的進展

基因工程的進步正在變革蛋白質工程，它能夠實現精確修飾，從而增強蛋白質的功能和穩定性。人工智慧驅動的蛋白質設計正在加速開發具有最佳化結構和特定功能的新型蛋白質。定向進化技術透過模擬自然選擇來最佳化蛋白質特性，提高效率和性能。合成生物學方法整合基因迴路，為製藥、食品和工業應用設計客製化蛋白質。重組去氧核糖核酸（DNA）技術能夠大規模生產具有優異生物活性和低免疫抗原性的客製化蛋白質。基因合成技術的創新正在簡化針對特定生化應用的客製化人工蛋白質序列的建構。蛋白質折疊模擬提高了結構預測的準確性，從而能夠精確設計具有所需特性的蛋白質。先進的表達系統正在提高用於商業性和醫療應用的蛋白質的產量、穩定性和生物利用度。代謝工程正在最佳化生物合成途徑，以提高微生物和植物來源宿主中的蛋白質產量。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球蛋白質工程市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品及服務分類

  • 裝置
  • 試劑
  • 服務和軟體

第7章 市場區隔：依蛋白質類型分類

  • 胰島素
  • 單株抗體
  • 凝血因子
  • 疫苗
  • 生長因子
  • 其他

第8章 市場區隔：依技術分類

  • 非理性蛋白質設計
  • 合理蛋白質設計

第9章 市場區隔：依最終用戶分類

  • 製藥和生物技術公司
  • 學術研究機構
  • 受託研究機構

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abzena Limited
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories Inc.
    • Bruker Corporation
    • Codexis Inc.
    • DH Life Sciences, LLC
    • GenScript
    • Merck KGaA
    • Novo Nordisk A/S
    • Protomer Technologies（Eli Lilly and Company）
    • Revvity, Inc.
    • Thermo Fisher Scientific Inc.
    • Waters Corporation
Product Code: SR112026A5005

The global protein engineering market size was valued at USD 3.9 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 8.6 Billion by 2034, exhibiting a CAGR of 8.74% during 2026-2034. North America currently dominates the market, holding a significant market share of 40.6% in 2025. Artificial intelligence (AI-driven) automation enhances protein modeling, drug discovery, and industrial enzyme optimization, which is a key factor expanding the protein engineering market share. Government funding supports academic research, accelerating innovations in protein therapeutics and synthetic biology.

Government funding and academic research are accelerating advancements in the protein engineering market through innovation and commercialization. Public research grants support foundational studies in protein structure, function, and bioengineering applications. Government agencies allocate funds to universities for developing novel protein-based therapeutics and industrial enzymes. Research institutions collaborate with biotech firms to translate academic discoveries into commercial protein engineering solutions. Federal funding programs drive advancements in synthetic biology, enabling precision-designed proteins for diverse applications. Academic researchers optimize protein expression systems, improving scalability for pharmaceutical and industrial biomanufacturing. Government-backed initiatives promote AI-driven protein modeling, enhancing drug discovery and targeted therapy development. Academic labs develop new gene editing techniques to refine protein modifications for enhanced functionality.

Artificial intelligence (AI)-driven automation is transforming the United States protein engineering market by enhancing efficiency, accuracy, and scalability. Machine learning (ML) algorithms predict protein structures, improving drug discovery and biopharmaceutical development processes. AI-powered tools optimize protein folding, stability, and functionality for therapeutic and industrial applications, thus catalyzing the protein engineering market demand. Automated high-throughput screening accelerates candidate selection, reducing time and costs for engineered protein development. Deep learning models analyze massive biological datasets, identifying novel protein sequences with targeted properties. AI-driven computational biology enhances rational protein design, refining molecular interactions and improving specificity. For instance, in November 2024, Imperial College London launched Imperial Global USA, its first physical presence in the United States, based in San Francisco. The hub aims to foster 100 new US-UK science and technology partnerships in 2025, with a focus on AI, robotics, cleantech, biotech, and engineering biology. Additionally, robotics streamline protein purification and characterization, minimizing errors and increasing experimental reproducibility. AI-integrated laboratory automation enhances efficiency in large-scale protein expression and biomanufacturing workflows, which further propels the market growth.

PROTEIN ENGINEERING MARKET TRENDS:

Expanding synthetic biology market

Increasing investments in synthetic biology and the growing emphasis on protein-based drug development are key drivers of the market. The global synthetic biology market was valued at USD 18.5 billion in 2024 and is projected to reach USD 66.7 billion by 2033, registering a 15.3% CAGR from 2025 to 2033, as per IMARC Group's report. Scientists are designing custom proteins with enhanced stability, specificity, and functionality for diverse industrial and healthcare uses. AI-driven algorithms and CRISPR-based modifications are enabling precise protein modifications for tailored therapeutic and industrial applications. Engineered proteins are revolutionizing drug discovery, enzyme manufacturing, and bio-based materials with increased efficiency and sustainability. Companies are leveraging synthetic biology tools to develop novel biocatalysts for green chemistry and sustainable production methods. Precision fermentation techniques are producing alternative proteins with improved nutritional profiles and functional properties. Bio-based materials from engineered proteins are replacing traditional petrochemical-based products in textiles and packaging. Advancements in metabolic pathway engineering are expanding protein functionality for enhanced enzymatic activity in bioprocessing applications, which is strengthening the market growth.

Rising prevalence of protein-deficient diseases

The high prevalence of protein-deficient diseases is driving the demand for protein engineering. Studies report that 2-10% of children aged 1-9 in developing nations experience severe protein-calorie malnutrition, while in some regions, up to 50% of children aged 1-5 suffer from milder deficiencies. Malnutrition-related disorders and genetic conditions requiring protein supplementation are influencing advancements in protein engineering technologies. Engineered proteins are being developed to address metabolic disorders, enzyme deficiencies, and hereditary protein-related diseases effectively. Biopharmaceutical companies are designing recombinant proteins for treating conditions like cystic fibrosis, hemophilia, and growth hormone deficiencies. Advancements in protein engineering are enabling the production of bioavailable therapeutic proteins with enhanced stability and efficacy. Researchers are modifying protein structures to improve absorption, half-life, and targeted delivery for clinical applications. Increased awareness about protein-deficient diseases is encouraging investment in precision-engineered proteins for personalized medicine solutions. Growing demand for plant-based and fermentation-derived proteins is addressing dietary protein deficiencies in global populations.

Advancements in genetic engineering

Advancements in genetic engineering are transforming protein engineering by enabling precise modifications for enhanced functionality and stability. AI-driven protein design is accelerating the development of novel proteins with optimized structures and specific functions. Directed evolution techniques are refining protein properties by mimicking natural selection for better efficiency and performance. Synthetic biology approaches are integrating genetic circuits to design custom proteins for pharmaceutical, food, and industrial uses. Recombinant deoxyribonucleic acid (DNA) technology is facilitating large-scale production of engineered proteins with superior bioactivity and reduced immunogenicity. Gene synthesis innovations are streamlining the creation of artificial protein sequences tailored for specialized biochemical applications. Protein folding simulations are improving structural predictions, enabling precise engineering of proteins with desired characteristics. Advanced expression systems are enhancing protein yields, stability, and bioavailability for commercial and medical applications. Metabolic engineering is optimizing biosynthetic pathways for increased protein production in microbial and plant-based hosts.

PROTEIN ENGINEERING INDUSTRY SEGMENTATION:

Analysis by Product & Services:

  • Instruments
  • Reagents
  • Services and Software

Instruments stand as the largest component in 2025, holding 53.2% of the market. Advanced analytical instruments enable precise protein characterization, structural analysis, and functional optimization for various applications. High-performance chromatography systems and spectroscopy instruments enhance protein purification and identification processes effectively. Mass spectrometry technologies facilitate accurate protein sequencing, modifications analysis, and molecular weight determination for engineering applications. Automated liquid handling systems streamline high-throughput screening, improving efficiency in protein engineering workflows. Cutting-edge imaging technologies provide real-time insights into protein interactions and conformational changes. Next-generation sequencing (NGS) platforms support genetic modifications and structural modeling for protein engineering advancements. Increased adoption of microfluidics-based devices enhances miniaturized protein assays and accelerates screening processes. Companies invest in instrument development to improve reproducibility, accuracy, and scalability in protein engineering experiments. Rising demand for customized protein structures drives innovation in instrument technologies for targeted design applications. Pharmaceutical and biotech firms rely on advanced instruments for biologics development and structural biology research. Expanding government and private funding boosts investment in instrument-based research infrastructure.

Analysis by Protein Type:

  • Insulin
  • Monoclonal Antibodies
  • Coagulation Factors
  • Vaccines
  • Growth Factors
  • Others

In 2025, monoclonal antibodies dominate the market, holding a 24.5% market share. These designed proteins are crucial in targeted drug treatments, especially for cancer and autoimmune disorders. Cutting-edge protein engineering methods enhance monoclonal antibodies for better specificity, stability, and therapeutic effectiveness. The growing occurrence of chronic illnesses is fueling the need for antibody-based therapies in biopharmaceutical uses. Biotech firms concentrate on creating advanced monoclonal antibodies that offer improved binding affinity and decreased immunogenicity. Recombinant DNA techniques allow for the intensive production of monoclonal antibodies that are highly pure and yield substantial amounts. Growing regulatory approvals for antibody-based biologics continue to enhance their market leadership in protein engineering. AI-powered protein optimization speeds up the discovery of monoclonal antibodies, decreasing both time and expense in drug development. Collaborative strategies between biotech startups and pharmaceutical companies enhance the research and marketability of monoclonal antibodies. Increasing demand for biosimilars and antibody-drug conjugates boosts market expansion in this sector. Improvements in hybridoma technology and phage display lead to ongoing advancements in the engineering of monoclonal antibodies.

Analysis by Technology :

  • Irrational Protein Design
  • Rational Protein Design

Rational protein design holds the largest market share due to its precision and efficiency in protein modification. This approach utilizes computational modeling and AI-driven algorithms to predict and optimize protein structures effectively. Scientists design proteins with desired properties by modifying specific amino acid sequences and functional sites. Structural bioinformatics and molecular docking simulations enhance rational protein design applications in drug development. AI and ML significantly improve protein modeling accuracy, accelerating discovery and optimization processes. High-throughput screening techniques validate designed proteins, ensuring optimal stability and performance in applications. Rational protein design reduces trial-and-error methods, leading to faster, cost-effective protein engineering solutions. Pharmaceutical companies leverage this technology for antibody engineering, enzyme optimization, and therapeutic protein development. Continuous advancements in computational tools enhance rational design's efficiency for industrial and medical applications. Academic research institutions collaborate with biotech firms to refine rational protein design methodologies. Expanding use in enzyme engineering for industrial bioprocessing strengthens its market share in protein engineering.

Analysis by End User:

  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations

Pharmaceutical and biotechnology companies dominate the market with 45.3% of market share in 2025. These firms drive innovation in therapeutic proteins, monoclonal antibodies, and enzyme-based drug development. Biopharmaceutical companies invest heavily in protein engineering to enhance drug efficacy and safety. AI-driven protein design accelerates biologic drug discovery, reducing costs and development timelines. Increased prevalence of chronic diseases increases demand for protein-based biologics in targeted therapies. Expanding applications of engineered proteins in oncology, immunology, and metabolic disorders strengthen market growth. Regulatory approvals for biologics encourage pharmaceutical firms to develop next-generation protein therapeutics. Biotech startups focus on synthetic biology and precision fermentation for sustainable protein-based solutions. Collaborations between pharmaceutical giants and academic institutions advance protein engineering research and commercialization. Continuous innovation in recombinant protein production improves scalability and cost-effectiveness in manufacturing. Rising adoption of engineered enzymes in drug formulation enhances the sector's market share.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of 40.6%. The region hosts major biotech and pharmaceutical firms driving innovation in engineered proteins. Increased investment in AI-driven protein design strengthens North America's leadership in protein engineering. Government funding supports academic research institutions engaged in protein engineering advancements. Expanding clinical trials for biologics and monoclonal antibodies boost protein-based drug development. Regulatory agencies, including the FDA, streamline approvals for engineered protein therapeutics. High adoption of precision fermentation and synthetic biology enhances protein engineering applications. North American companies leverage AI and machine learning for rational protein design and optimization. Strong demand for biopharmaceuticals drives growth in engineered protein-based therapies. For example, In November 204, Future Fields, a Canadian biotech company, opened Instar 1.0, a 6,000-square-foot facility in Edmonton dedicated to fruit fly-based biomanufacturing. This innovative approach addresses biomanufacturing challenges by offering a more efficient and scalable protein production method. Instar 1.0 enables custom protein synthesis in exotic cell lines, supporting research into next-generation therapies. This advancement is particularly impactful for the Protein Engineering market, providing a novel platform for producing complex proteins essential for therapeutic applications. Moreover, expanding partnerships between academia and industry foster continuous innovation in protein engineering. Robust venture capital investment fuels biotech startups focused on next-generation protein therapeutics. Leading research universities contribute to groundbreaking discoveries in engineered protein applications.

KEY REGIONAL TAKEAWAYS:

UNITED STATES PROTEIN ENGINEERING MARKET ANALYSIS

The United States accounts for 89.60% of the protein engineering market share in North America, driven by increasing demand for biologics, such as monoclonal antibodies and biosimilars. Rising chronic disease prevalence, with an estimated 129 million Americans affected by conditions like heart disease, cancer, diabetes, obesity, and hypertension, is driving demand for protein-based therapeutics. Strong research and development (R&D) investments, a well-established biopharmaceutical industry, and favorable regulatory policies support continuous advancements in protein engineering. AI-driven protein modeling and CRISPR-based gene editing are improving drug discovery and protein optimization processes. The expansion of synthetic biology applications in personalized medicine, enzyme engineering, and agriculture further strengthens market growth. Government initiatives promoting biopharmaceutical research, tax incentives, and intellectual property protections encourage innovation and commercialization. Collaborations between pharmaceutical companies, research institutions, and biotech startups accelerate new protein-based drug development. Industrial applications, including biofuels, food processing, and environmental biotechnology, are also influencing protein engineering adoption. The presence of advanced healthcare infrastructure, strong financial support, and increasing venture capital investments induces sector's growth. Continuous technological advancements in protein characterization, structural biology, and metabolic engineering further solidify the US market's leadership in global protein engineering innovations.

ASIA PACIFIC PROTEIN ENGINEERING MARKET ANALYSIS

The Asia Pacific market is expanding due to rising investments in biotechnology and pharmaceutical research and development (R&D), supported by favorable government policies. The increasing cancer incidence, recorded at 169.1 per 100,000 in 2020 and accounting for 49.3% of global cases, is driving demand for engineered proteins in targeted therapies. Expanding biopharmaceutical manufacturing capabilities in China, India, and South Korea further fueling market growth. Leading academic and research institutions are fostering innovation in protein engineering technologies. Growing adoption of synthetic biology and CRISPR-based protein modifications is advancing precision medicine applications. Collaborations between global biotech firms and regional players facilitate technology transfer and commercialization. The demand for personalized medicine, along with a skilled workforce at competitive costs, strengthens regions market position. Expansion of biopharma contract development and manufacturing organizations (CDMOs) is increasing production capacity and efficiency. Supportive regulatory frameworks, rising healthcare expenditure, and government-backed initiatives enhance industry development. The increasing focus on monoclonal antibodies, biosimilars, and next-generation biologics further accelerates protein engineering adoption. Strengthening infrastructure for AI-driven drug discovery and large-scale biomanufacturing ensures sustained growth. Overall, the regions dynamic biopharmaceutical sector and strong research ecosystem position the region as a key player in protein engineering advancements.

EUROPE PROTEIN ENGINEERING MARKET ANALYSIS

The European market is expanding due to a strong biotechnology sector backed by significant public and private investments. Rising demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and gene therapies, is driving advancements in protein engineering technologies. With the European Union population reaching 448.8 million in 2023 and 21.3% aged 65 and above, the increasing prevalence of chronic and age-related diseases is catalyzing demand for innovative protein-based therapeutics. Favorable regulatory policies, such as expedited biologic approvals, further support market growth. Region's well-established biomanufacturing infrastructure, particularly in Germany, Switzerland, and the UK, strengthens protein production capabilities. Strategic partnerships between academic institutions, biotech firms, and pharmaceutical companies are enhancing research-driven innovation in protein engineering. Expanding contract development and manufacturing organization (CDMO) capabilities improve scalability and efficiency in biopharmaceutical production. Increasing adoption of AI-driven protein design, precision medicine, and sustainable bioprocessing further influencing industry demand. Government initiatives supporting biosimilars and next-generation biologics accelerate innovation and commercialization. AI and ML integration in protein engineering enhance drug discovery and structural optimization. Growing investments in cell and gene therapy are further driving industry expansion. With a rising elderly population, increasing healthcare needs, and continued focus on biologics, Europe remains a key global player in protein engineering advancements.

LATIN AMERICA PROTEIN ENGINEERING MARKET ANALYSIS

Latin America's market is growing due to rising biotechnology investments, increasing biologics demand, and improving healthcare infrastructure. The region faces a significant chronic disease burden, with Brazil alone reporting approximately 928,000 deaths annually from chronic illnesses, driving the need for innovative protein-based therapeutics. Governments are actively supporting biotech innovation through favorable policies, research funding, and foreign investment incentives. Expanding biosimilar adoption and collaborations between universities, research institutions, and global biotech firms are accelerating market development. Additionally, protein engineering applications in food processing and agriculture are gaining prominence. Competitive biomanufacturing costs position Latin America as an emerging hub for biopharmaceutical production and innovation.

MIDDLE EAST AND AFRICA PROTEIN ENGINEERING MARKET ANALYSIS

The Middle East and Africa region market is expanding due to rising healthcare investments, growing biopharmaceutical manufacturing, and an increasing chronic disease burden. In the UAE, 23% of individuals report chronic illnesses, with obesity (12.5%), diabetes (4.2%), and asthma/allergies (3.2%) being the most common, driving demand for protein-based therapeutics. Governing agencies of Saudi Arabia and the UAE are investing heavily in biotechnology research and personalized medicine to advance healthcare innovation. Collaborations with global biotech firms and academic institutions are strengthening regional research and development (R&D) capabilities. Expanding applications in food processing, industrial enzymes, and biosimilar production, along with improving regulatory frameworks, are further supporting market growth.

COMPETITIVE LANDSCAPE:

Leading biotechnology companies are investing heavily in AI-driven protein design to optimize molecular structures efficiently. Pharmaceutical firms are utilizing engineered proteins for developing targeted therapies, biologics, and enzyme-based treatments. In April 2024, Abzena Ltd. launched EpiScreen 2.0, an advanced platform for immunogenicity assessment, enhancing the development of complex biologics and bioconjugates. Leveraging over 20 years of expertise from the original EpiScreen platform, this next-generation suite delivers highly sensitive, multi-parametric, and data-rich assays to predict and evaluate preclinical immunogenicity risks in proteins, antibodies, and gene therapy therapeutics. Additionally, synthetic biology startups are introducing novel protein engineering approaches for food, healthcare, and industrial applications. Contract research organizations are supporting drug discovery by providing protein engineering solutions for biopharma clients. Academic institutions are advancing protein engineering techniques through collaborations with biotech companies and government research programs. Investments in precision fermentation are enabling large-scale production of engineered proteins for various commercial applications. Mergers and acquisitions are strengthening the market by integrating expertise in protein design and biomanufacturing. Companies are forming strategic alliances to accelerate protein-based drug development and industrial enzyme production.

The report provides a comprehensive analysis of the competitive landscape in the protein engineering market with detailed profiles of all major companies, including:

  • Abzena Limited
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories Inc.
  • Bruker Corporation
  • Codexis Inc.
  • DH Life Sciences, LLC
  • GenScript
  • Merck KGaA
  • Novo Nordisk A/S
  • Protomer Technologies (Eli Lilly and Company)
  • Revvity, Inc.
  • Thermo Fisher Scientific Inc.
  • Waters Corporation

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Protein Engineering Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product & Services

  • 6.1 Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Reagents
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Services and Software
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Protein Type

  • 7.1 Insulin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Monoclonal Antibodies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Coagulation Factors
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Vaccines
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Growth Factors
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Irrational Protein Design
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Rational Protein Design
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical and Biotechnology Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Academic Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Contract Research Organizations
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abzena Limited
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agilent Technologies, Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bio-Rad Laboratories Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bruker Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Codexis Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 DH Life Sciences, LLC
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GenScript
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck KGaA
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novo Nordisk A/S
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Protomer Technologies (Eli Lilly and Company)
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Revvity, Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Thermo Fisher Scientific Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Waters Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Protein Engineering Market: Major Drivers and Challenges
  • Figure 2: Global: Protein Engineering Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Protein Engineering Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Protein Engineering Market: Breakup by Product & Services (in %), 2025
  • Figure 5: Global: Protein Engineering Market: Breakup by Protein Type (in %), 2025
  • Figure 6: Global: Protein Engineering Market: Breakup by Technology (in %), 2025
  • Figure 7: Global: Protein Engineering Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Protein Engineering Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Protein Engineering (Instruments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Protein Engineering (Instruments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Protein Engineering (Reagents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Protein Engineering (Reagents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Protein Engineering (Services and Software) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Protein Engineering (Services and Software) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Protein Engineering (Insulin) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Protein Engineering (Insulin) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Protein Engineering (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Protein Engineering (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Protein Engineering (Coagulation Factors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Protein Engineering (Coagulation Factors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Protein Engineering (Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Protein Engineering (Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Protein Engineering (Growth Factors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Protein Engineering (Growth Factors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Protein Engineering (Other Protein Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Protein Engineering (Other Protein Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Protein Engineering (Irrational Protein Design) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Protein Engineering (Irrational Protein Design) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Protein Engineering (Rational Protein Design) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Protein Engineering (Rational Protein Design) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Protein Engineering (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Protein Engineering (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Protein Engineering (Academic Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Protein Engineering (Academic Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Protein Engineering (Contract Research Organizations) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Protein Engineering (Contract Research Organizations) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: North America: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: North America: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: United States: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: United States: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Canada: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Canada: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Asia-Pacific: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Asia-Pacific: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: China: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: China: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Japan: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Japan: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: India: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: India: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: South Korea: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: South Korea: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Australia: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Australia: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Indonesia: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Indonesia: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Others: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Others: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Europe: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Europe: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Germany: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Germany: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: France: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: France: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: United Kingdom: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: United Kingdom: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Italy: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Italy: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Spain: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Spain: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Russia: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Russia: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Latin America: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Latin America: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Brazil: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Brazil: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Mexico: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Mexico: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Others: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Others: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Middle East and Africa: Protein Engineering Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Middle East and Africa: Protein Engineering Market: Breakup by Country (in %), 2025
  • Figure 85: Middle East and Africa: Protein Engineering Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Global: Protein Engineering Industry: SWOT Analysis
  • Figure 87: Global: Protein Engineering Industry: Value Chain Analysis
  • Figure 88: Global: Protein Engineering Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Protein Engineering Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Protein Engineering Market Forecast: Breakup by Product & Services (in Million USD), 2026-2034
  • Table 3: Global: Protein Engineering Market Forecast: Breakup by Protein Type (in Million USD), 2026-2034
  • Table 4: Global: Protein Engineering Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 5: Global: Protein Engineering Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Protein Engineering Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Protein Engineering Market: Competitive Structure
  • Table 8: Global: Protein Engineering Market: Key Players